# US 2010/0303878 A1 · Biodegradable bioactive agent releasing matrices with particulates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303878 A1
- Document ID: US20100303878A1
- Status: Published application
- Kind: A1
- Application number: 12/792,309
- Filed: 2010-06-02
- Published: 2010-12-02
- Earliest claimed: 2009-06-02
- Inventors: Joram Slager; Robert Hergenrother
- Web page: https://patentgrep.com/patent/US20100303878A1

## CPC

- A61K 39/39591: {Stabilisation, fragmentation}
- A61L 17/005: {containing a biologically active substance, e.g. a medicament or a biocide}
- A61L 17/145: {Coating}
- A61L 27/34: Macromolecular materials
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 29/085: {Macromolecular materials}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 31/10: Macromolecular materials
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 35/00: Antineoplastic agents
- A61L 2300/256: Antibodies, e.g. immunoglobulins, vaccines
- A61L 2300/624: Nanocapsules
- C07K 2317/55: Fab or Fab'
- Y10T 428/31663: As siloxane, silicone or silane
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention is directed to biodegradable polymeric matrices for the controlled release of a hydrophilic bioactive agent. Generally, the biodegradable matrices include an aliphatic polyester copolymer and microparticulates that include the hydrophilic bioactive agent. In some embodiments, the matrix includes a second biodegradable polymer comprising hydrophilic and hydrophobic portions. Exemplary matrix forms are device coatings and medical implants. Matrices of the invention demonstrated high bioactive agent loading, were able to modulate release of the bioactive agent in a therapeutic manner, and also maintained high levels of activity for therapeutically useful large molecule bioactive agents, such as proteins.

## Claims

### Claim 1

A biodegradable bioactive agent-releasing matrix, comprising a polymeric matrix comprising:
a biodegradable aliphatic polyester copolymer comprising monomeric units of formula I:
wherein R1 is a divalent saturated or unsaturated hydrocarbon group that includes two carbon atoms, and wherein the monomeric units of formula I are present in the biodegradable aliphatic polyester copolymer in an amount of greater than 17% by weight; and
a plurality of microparticles dispersed within the matrix; wherein the microparticles comprise a hydrophilic bioactive agent,
wherein the biodegradable bioactive agent-releasing matrix comprises a surface that is placed in direct contact with body fluid and/or body tissue.

### Claim 2

A biodegradable bioactive agent-releasing matrix, comprising a polymeric matrix comprising:
a first biodegradable copolymer comprising a biodegradable aliphatic polyester copolymer comprising monomeric units of formula II:
wherein R2 is a divalent saturated or unsaturated hydrocarbon group that includes four or five carbon atoms, and wherein the monomeric units of formula II are present in the biodegradable aliphatic polyester copolymer in an amount of greater than 15% by weight;
a second biodegradable copolymer comprising hydrophobic and hydrophilic portions; and
a plurality of microparticles dispersed within the matrix; wherein the microparticles comprise a hydrophilic bioactive agent.

### Claim 3 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2, wherein the monomeric units of formula II are present in the biodegradable aliphatic polyester copolymer in an amount in the range of 15% to 80% by weight.

### Claim 4 (depends on 3)

The biodegradable bioactive agent-releasing matrix of claim 3, wherein the monomeric units of formula I are present in the biodegradable aliphatic polyester copolymer in an amount in the range of 25% to 75% by weight.

### Claim 5 (depends on 2)

The elution control matrix of claim 2, wherein the monomeric units of formula II are derived from the polymerization of caprolactone.

### Claim 6 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2, wherein the biodegradable aliphatic polyester copolymer further comprises monomeric units of formula I:
wherein R1 is a divalent saturated or unsaturated hydrocarbon group that includes two carbon atoms.

### Claim 7 (depends on 6)

The biodegradable bioactive agent-releasing matrix of claim 6, wherein the monomeric units of formula II are present in the biodegradable aliphatic polyester copolymer in an amount in the range of 20% to 85% by weight.

### Claim 8 (depends on 7)

The biodegradable bioactive agent-releasing matrix of claim 7, wherein the monomeric units of formula II are present in the biodegradable aliphatic polyester copolymer in an amount in the range of 25% to 75% by weight.

### Claim 9 (depends on 6)

The biodegradable bioactive agent-releasing matrix of claim 6, wherein the monomeric units of formula I are derived from the polymerization of lactide.

### Claim 10 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2, wherein the first biodegradable polymer and second biodegradable polymer are present in the matrix in a ratio in the range of 1:10 to 10:1 by weight.

### Claim 11 (depends on 10)

The biodegradable bioactive agent-releasing matrix of claim 10, wherein the first biodegradable polymer and second biodegradable polymer are present in the matrix in a ratio in the range of 1.5:10 to 10:1.5 by weight.

### Claim 12 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2 wherein the second biodegradable polymer includes hydrophilic polymeric blocks and hydrophobic polymeric blocks, with one or both blocks including degradable linkages

### Claim 13 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2 wherein the second biodegradable polymer includes polyethylene glycol blocks.

### Claim 14 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2 wherein the second biodegradable copolymer comprises a polyether ester copolymer.

### Claim 15 (depends on 14)

The biodegradable bioactive agent-releasing matrix of claim 14 wherein the second biodegradable copolymer comprises a poly(ether ester) block copolymer comprising poly(ethylene glycol) (PEG) and poly(butylene terephthalate) (PBT) blocks.

### Claim 16 (depends on 14)

The biodegradable bioactive agent-releasing matrix of claim 14 wherein the second biodegradable copolymer comprises a block copolymer comprising poly(ethylene glycol) (PEG) and poly(lactic acid) (PLA) blocks.

### Claim 17 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2 wherein the microparticles are present in the matrix in an amount in the range of 1% to 50% by weight of a total solids content of the matrix.

### Claim 18 (depends on 16)

The biodegradable bioactive agent-releasing matrix of claim 16 wherein the microparticles are present in the matrix in an amount in the range of 20% to 40% by weight of a total solids content of the matrix.

### Claim 19 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2 wherein the microparticles comprise a polypeptide.

### Claim 20 (depends on 19)

The biodegradable bioactive agent-releasing matrix of claim 19, wherein the microparticles comprises a polypeptide that is an antibody or fragment thereof.

### Claim 21 (depends on 20)

The biodegradable bioactive agent-releasing matrix of claim 20, wherein the microparticles comprises a Fab fragment.

### Claim 22 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2, wherein the microparticles are formed predominantly of the hydrophilic bioactive agent.

### Claim 23 (depends on 2)

The biodegradable bioactive agent-releasing matrix of claim 2, which is in the form of a coating on an implantable medical device.

### Claim 24 (depends on 2)

A method for affecting a condition in a subject comprising the steps of introducing the biodegradable bioactive agent-releasing matrix of claim 2 in a subject, and allowing hydrophilic bioactive agent to be released from the elution control matrix which affects the condition in a subject.
